A Single-arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte (GT201 Injection ) in Combination with Teraplizumab Injection for Treatment of Patients with Non-small Cell Lung Cancer
This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT201 injection ) in combination with teraplizumab injection for treatment of patients with non-small cell lung cancer,while evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose (OBD).
• 1\. Voluntarily join the study, signed informed consent form,, willing and able to comply with the study protocol;
• 2\. Age 18 to 70 years old;
• 3\. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
• 4\. Expected survival time of ≥ 12 weeks;
• 5\. Good function of vital organs;
• 6\. Subjects entering this study due to disease progression must have an imaging record of disease progression before tumor sampling;
• 7\. At least one measurable target lesion that meets the definition of RECIST v1.1 after tumor sampling.